Immunohistochemistry frequently detects c-kit expression in pulmonary small cell carcinoma and may help select clinical subsets for a novel form of chemotherapy

Applied Immunohistochemistry and Molecular Morphology

Volumn 11, Issue 1, 2003, Pages 51-55

  Lonardo, Fulvio ^a,b   Pass, Harvey Ira ^a   Lucas, David Robert ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Antineoplastic agents; c Kit; Pulmonary neoplasms; Small cell carcinoma; STI571 Immunohistochemistry; Tyrosine kinase receptor

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CARCINOID; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INCIDENCE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

EID: 0345382780     PISSN: 15412016     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129039-200303000-00009     Document Type: Article

References (11)

1. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissue: value in the diagnosis of mast cell disorders. Hum Pathol 1998;29:498-504.
2. Tsuura Y, Hiraki H, Watanabe K, et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 1994;424:135-41.
3. Matsuda R, Takahashi T, Nakamura S, et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 1993;142:339-46.
4. Natali PG, Nicotra MR, Sures I, et al. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992;52:6139-6143.
5. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996;56:370-6.
6. Sekido Y, Obata Y, Ueda R, et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 1991;51:2416-9.
7. Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997; 23:380-94.
8. Hehlmann R, Hochhaus A, Berger U, et al. Current trends in the management of chronic myelogenous leukemia. Ann Hematol 2000;79:345-54.
9. Krystal GW, Honsawek S, Litz J, et al. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 2000;6:3319-26.
10. Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel kinase inhibitor STI571. Oncogene 2000;19:3521-8.
11. Dan S, Naito M, Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell Death Differ 1998;5:710-5.